Halberd Corporation (OTC PINK: HALB), after recognizing the depth of application of its recently patented extracorporeal treatment approach, has announced the creation of a new subsidiary. The subsidiary comprises a group of researchers focusing on cancer treatment. The technology invented by Halberd can be applied to treat different diseases. Hence, the company’s management has decided not to waste time on developing potential cancer treatments.
Halberd’s existing technical team members will lead the subgroup. However, the team is expected to add the necessary expertise to achieve the corporation’s goal without diluting its current efforts toward reducing neurodegenerative diseases, such as Alzheimer’s Disease (AD), Epilepsy, Suicide Ideation, and PTSD/Chronic Traumatic Encephalopathy (CTE), Depression, etc. Halberd’s technology has also proved that it is effective against bacterial and viral infections as well.
Halberd Corporations expects that this new cancer subgroup will eventually be spun off as a separate entity which will serve as a dividend to the corporation’s stakeholders. Through this strategy, Halberd will not only help share its accomplishments with the world but also earn benefits from royalties from applying cancer treatments.
Halberd’s Chief Technology Officer and board-certified attending neurologist, Dr. Mitchell S. Felder, said, “Our earlier experience with the cancer antibodies development, coupled with the recent successes we demonstrated eliminating targeted inflammatory cytokines, proteins etc., leads me to believe that this may be the initial step towards developing a cure for a wide variety of cancers. Our plan is to develop three major cancer antibodies (PD-1. BTLA, and CTLA-4) that could be used to effectively eradicate many cancers while employing Halberd’s patented extracorporeal eradication methodology. We plan to test these antibodies for efficacy in the laboratory, near term.”
The chairman, CEO, and President of Halberd Corporation also added, “We believe that the creation of a subgroup and separate Cancer Treatment Division of the Halberd Corporation is a viable and prudent step in creating not only a more effective and less debilitating treatment for cancer but for creating tremendous shareholder value.”
Featured Image: DepositPhotos © nikesidoroff
